EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis
EydisBio is a start-up founded by Professor Timothy Haystead (P&CB, SOM) focusing on the treatment of autoimmune and inflammatory diseases.
Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups
$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.
Sparta Biomedical Reports Treatment of First Patients with Breakthrough Device, Ormi
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry, Trinity), and colleagues.
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences is a Duke University start-up run by CEO Deborah Bitterfield (PhD MEMS, Pratt) based on technology developed in the lab of Professor Emeritus David Needham (MEMS, Pratt).
New therapy for glioma receives FDA approval, leveraging cancer research conducted at Johns Hopkins & Duke University
Drs. Darell Bigner and Hai Yan (Neurosurgery, SOM) and colleagues identified the genetic mutation targeted by this new drug. Dr. Katherine Peters (Neurosurgery, SOM) was lead investigator in the clinical trials.
The Kardashians Take Longevity Test that Reveals Biological Age in ‘The Kardashians’ Upcoming Season Finale
Kardashians use biological age algorithm technology developed by Professors Terrie Moffitt & Avshalom Caspi (Psychology & Neuroscience, Trinity) and licensed to TruDiagnostics.
VQ Biomedical receives $750K grant from BARDA / ASPR / HHS
VQ Biomedical is a start-up resulting from the collaboration of Assistant Professor Tobias Straube (Pediatrics, SOM) and Research Scientist Stewart Farling (CEE, Pratt).